Therapy of Primary Liver Cancer

Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide. PLC is the leading cause of cancer-related deaths and the incidence rate is predicted to rise in the coming decades. PLC can be categorized into three major histological subtypes: hepatocellular carcinoma (HCC),...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Mei, Pan, Yisheng, Kong, Ruirui, Shu, Shaokun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416132/
https://www.ncbi.nlm.nih.gov/pubmed/32914142
http://dx.doi.org/10.1016/j.xinn.2020.100032
_version_ 1783569267845758976
author Feng, Mei
Pan, Yisheng
Kong, Ruirui
Shu, Shaokun
author_facet Feng, Mei
Pan, Yisheng
Kong, Ruirui
Shu, Shaokun
author_sort Feng, Mei
collection PubMed
description Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide. PLC is the leading cause of cancer-related deaths and the incidence rate is predicted to rise in the coming decades. PLC can be categorized into three major histological subtypes: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined HCC-ICC. These subtypes are distinct with respect to epidemiology, clinicopathological features, genetic alterations, and clinical managements, which are thoroughly summarized in this review. The state of treatment strategies for each subtype, including the currently approved drugs and the potential novel therapies, are also discussed.
format Online
Article
Text
id pubmed-7416132
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74161322020-08-10 Therapy of Primary Liver Cancer Feng, Mei Pan, Yisheng Kong, Ruirui Shu, Shaokun Innovation (Camb) Review Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide. PLC is the leading cause of cancer-related deaths and the incidence rate is predicted to rise in the coming decades. PLC can be categorized into three major histological subtypes: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined HCC-ICC. These subtypes are distinct with respect to epidemiology, clinicopathological features, genetic alterations, and clinical managements, which are thoroughly summarized in this review. The state of treatment strategies for each subtype, including the currently approved drugs and the potential novel therapies, are also discussed. Elsevier 2020-08-10 /pmc/articles/PMC7416132/ /pubmed/32914142 http://dx.doi.org/10.1016/j.xinn.2020.100032 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Feng, Mei
Pan, Yisheng
Kong, Ruirui
Shu, Shaokun
Therapy of Primary Liver Cancer
title Therapy of Primary Liver Cancer
title_full Therapy of Primary Liver Cancer
title_fullStr Therapy of Primary Liver Cancer
title_full_unstemmed Therapy of Primary Liver Cancer
title_short Therapy of Primary Liver Cancer
title_sort therapy of primary liver cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416132/
https://www.ncbi.nlm.nih.gov/pubmed/32914142
http://dx.doi.org/10.1016/j.xinn.2020.100032
work_keys_str_mv AT fengmei therapyofprimarylivercancer
AT panyisheng therapyofprimarylivercancer
AT kongruirui therapyofprimarylivercancer
AT shushaokun therapyofprimarylivercancer

Ejemplares similares